Georgiamune

Georgiamune is a private, preclinical-stage biotech leveraging a proprietary target discovery platform to develop novel immunomodulators. The company's strategy centers on rebalancing the immune system with first-in-class assets, including a dual-functioning antibody for cancer and small molecules that either inhibit or activate regulatory T cells (Tregs) for cancer and autoimmune diseases, respectively. Headquartered in Gaithersburg, MD, Georgiamune is building a portfolio aimed at large indications with high unmet need. It operates as a pre-revenue company with a team experienced in biopharma R&D.

Immunology-focused target discovery platform for identifying novel signaling pathways, leading to the development of dual-functioning antibodies and immune-reprogramming small molecules designed to rebalance the immune system.

In oncology, Georgiamune competes with numerous companies developing next-gen immuno-oncology agents beyond PD-1, including other Treg-modulating therapies. In autoimmunity, it faces competition from both established biologics and a new wave of targeted therapies, though its specific Treg-activation mechanism may differentiate it.